Menu Search
Equities

Intervacc AB

2E9:BER

Intervacc AB

Actions
  • Price (EUR)0.1766
  • Today's Change-0.005 / -2.54%
  • Shares traded--
  • 1 Year change-69.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 16:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

  • Revenue in SEK (TTM)9.78m
  • Net income in SEK-102.66m
  • Incorporated1983
  • Employees15.00
  • Location
    Intervacc ABVastertorpsvagen 135HAGERSTEN 129 44SwedenSWE
  • Phone+46 812010600
  • Fax+46 812010640
  • Websitehttp://intervacc.se/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.